Closing Bell: ASX takes the scenic route to absolutely nowhere

The ASX coughed up almost all of an early 0.6% gain to finish barely higher, as weak US jobs cooled Fed hike bets and healthcare did most of the useful work.

Investors hedge their bets on US stocks against Aussie dollar risks

Many share investors are nervous about the Australian dollar as US stocks continue to beat the ASX.

Health Check: CSL places $500m-plus bet on rare kidney and liver disease drug candidate

CSL will pay an upfront US$355 million ($515m) to co-develop an external drug candidate aimed at treating rare kidney and liver diseases.

How savvy investors can avoid CGT on luxury collectibles

Luxury assets, from a rare whisky cask to watches and even Lego, can deliver windfalls – and some attract zero capital gains tax.

About one in eight cancers is linked to infection – antibiotics and antivirals are taking aim

With infectious disease linked to 12% of cancers globally, drug developers are advancing treatments that could help reduce cancer incidence and tackle antimicrobial resistance.

EDITOR'S MUST READS OF THE DAY

Inspired by a legend, Parbo Resources hunts gold in WA’s Murchison

Gold IPO Parbo Resources has enjoyed a good start to life on the ASX, chasing discoveries in WA's Mid West overlooked by previous explorers.

Kristie Batten: Moonlight basking in recent drilling success